

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

WEDNESDAY, JULY 30, 1969

U.S. SENATE,
MONOPOLY SUBCOMMITTEE OF THE
SELECT COMMITTEE ON SMALL BUSINESS,
Washington, D.C.

The subcommittee met, pursuant to recess, at 9:40 a.m., in room 318, Old Senate Office Building, Senator Gaylord Nelson (chairman of the subcommittee) presiding.

Present: Senators Nelson and Dole.

Also present: Benjamin Gordon, staff economist; Elaine C. Dye, clerical assistant; and James P. Duffy III, minority counsel.

Senator NELSON. Our witnesses this morning are Dr. Richard Pillard and Dr. Daniel Freedman.

We will hear first from Dr. Pillard, who is assistant professor of psychiatry at Boston University School of Medicine. And then we will hear from Dr. Freedman.

Your statement will be printed in full in the record,¹ and you may present it however you wish. If you desire to extemporize on any particular point, we would be happy to have you do so. I assume you have no objection if we ask questions as you proceed?

Dr. PILLARD. No, sir.

Senator NELSON. We are pleased to have both of you here today. We have been extensively exploring various aspects of prescription drugs, their use, pricing, and manufacture, and so forth. And you join a long list of very distinguished witnesses who have appeared before the committee in the past 2 years, or more than 2 years. And we are pleased that you are willing to take the time to make your contribution to the record that we are accumulating here on this important subject.

**STATEMENT OF DR. RICHARD C. PILLARD, ASSISTANT PROFESSOR
OF PSYCHIATRY, BOSTON UNIVERSITY SCHOOL OF MEDICINE,
BOSTON, MASS.**

Dr. PILLARD. Thank you, Mr. Chairman.

My name is Richard C. Pillard. I am a physician, assistant professor of psychiatry at Boston University School of Medicine and head of the basic studies unit of the psychopharmacology laboratory there. I am also the recipient of an NIMH Research Scientist Development Award.

¹ See p. 5414.